news
Motif Bio announces intention to float on AIM
3 February 2015 | By Motif Bio
Motif Bio plc is seeking to raise at least £4 million through a placing of new ordinary shares and admission to trading on AIM...
List view / Grid view
Hit-to-Lead
news
First patient enrolled in the New Drugs 4 Bad Bugs (ND4BB) programme
3 February 2015 | By Innovative Medicines Initiative (IMI)
Two years after the start of the Innovative Medicines Initiative (IMI)-funded New Drugs 4 Bad Bugs (ND4BB) programme, the first patient has been enrolled into a Phase 2 trial sponsored by MedImmune, the global biologics research and development arm of AstraZeneca. The trial with MEDI4893 is among mechanically ventilated intubated…
news
New Oncology and University Hospital Oslo announce genomic profiling collaboration
22 January 2015 | By B3C newswire
New Oncology and the University Hospital Oslo announced today that they have entered into a collaboration to identify alterations in cancer-related tumour genes that predict a patient’s response or resistance to targeted therapies...
news
Roche, Meiji and Fedora join forces to tackle increasing bacterial resistance to antibiotics
13 January 2015 | By Roche
Roche, Meiji Seika Pharma (Meiji) and Fedora announced that they have entered into a license agreement for the development and commercialization of OP0595, a beta-lactamase inhibitor in phase I clinical development...
news
Roche enters a broad strategic collaboration with Foundation Medicine in the field of molecular information in oncology
12 January 2015 | By Roche
Collaboration leverages both companies’ strengths to advance the progress of personalized treatments for patients with cancer...
news
Oxford Global Conferences received excellent feedback from the 2014 Drug Discovery USA Congress
8 January 2015 | By Oxford Global Conferences
Oxford Global Conferences were proud to present the Drug Discovery USA Congress this October in Boston, USA...
news
Trial finds cancer drug can block key signal in cancer growth and drug resistance
6 January 2015 | By The Institute of Cancer Research
An experimental cancer drug may block an important driver for the survival, growth and spread of cancer cells...
news
Key US patents granted for GPCR-focused drug discovery platform arising from pioneering research and translational expertise at MRC and MRC Technology
17 December 2014 | By MRC Technology
Structure-based drug discovery platform targets challenging GPCRs linked to human disease...
news
Midatech Pharma awarded EU grant funding to support training and research into glycan based multivalent immunotherapeutics
17 December 2014 | By Midatech Pharma
Midatech Pharma, a nanomedicine company developing and commercialising multiple therapeutic products to enhance the delivery of medicines in major diseases with high unmet medical needs, is pleased to announce that a consortium of academic and industry groups including Midatech has been awarded a €3.8 million European Union grant...
news
New targeted drugs could treat drug-resistant skin cancer
15 December 2014 | By The Institute of Cancer Research, London, and Cancer Research UK Manchester Institute
A brand new family of cancer drugs designed to block several key cancer-causing proteins at once could potentially treat incurable skin cancers, a major new study reports...
news
ZoBio and Domainex join forces to deliver crucial drug target information to support FORMA therapeutics’ drug discovery programs
10 December 2014 | By ZoBio and Domainex
ZoBio (Leiden, The Netherlands) and Domainex Ltd. (Cambridge, UK) announce a collaboration with FORMA Therapeutics (Watertown, MA, USA) to provide NMR-based structural biology services for a substantial panel of FORMA drug targets...
news
reViral receives over US$1Mn in funding
4 December 2014 | By reViral
Second tranche of Seeding Drug Discovery award from Wellcome Trust Innovations...
news
Evotec and Sanofi discuss major multi-component strategic collaboration
3 December 2014 | By Evotec
Evotec AG announced today that it has entered into exclusive negotiations with Sanofi on a major multi-component strategic alliance over the next five years.
news
BioVersys and Enamine announce extension of drug discovery collaboration to address multidrug-resistant bacterial infections
2 December 2014 | By BioVersys and Enamine
Enamine Ltd. and BioVersys AG announced the extension of their drug discovery collaboration for the 4th consecutive year...
news
International College of Neuropsychopharmacology (CINP) calls on governments to reverse ‘disturbing’ trend of lack of new drugs for the 10% of the global population affected by brain diseases
2 December 2014 | By The International College of Neuropsychopharmacology
The International College of Neuropsychopharmacology (CINP) has published a paper in Nature Reviews Drug Discovery on how global governments must act to address the dearth of new drugs for central nervous system (CNS) diseases...
